top of page
Untitled design.png
Screenshot_2023-09-15_at_11.33.09-removebg-preview.png

Pioneering 

The Next Generation

of Cancer Therapies

NAYA Therapeutics is a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of astatine-211 radiopharmaceuticals
and NK-cell-engaging bifunctional antibodies.


We aim to unlock deeper, more durable responses in patients not responding to current standard-of-care, with an initial focus on hepatocellular carcinoma (HCC) and multiple myeloma. 

MEDIA

Astatine-211 Webinar: NAYA’s Expansion into Radiopharmaceuticals
04:26
Astatine-211 Webinar: "The Cleanest of All The Alpha Emitters"
02:07
Astatine-211 Webinar: "The Astatine ATM"
02:33
Astatine-211 Webinar: "Putting Astatine-211's Potential in the Hands of Drug Developers"
02:25
Astatine-211 Webinar: "Minimal Residual Disease Is The Last Frontier in Oncology"
02:07
Astatine-211 Webinar: "Empowering Oncologists in the Fight Against Cancer"
01:18
Astatine-211 Webinar: "A Decentralized Supply Chain is a Derisked Supply Chain"
01:40
Astatine-211 Webinar: "An Opportunity You Cannot Miss"
02:15
bottom of page